Table 4.
Patients With MDR TB Treated With Linezolid With ≥1 Linezolid-Related Adverse Event—California, 2009–2016
| Overall (n = 69) | Standard-Dose Linezolid (600 mg/d; n = 39) | Low-Dose Linezolid (Intermittent Dose and 300-mg Daily Dose; n = 30) | Intermittent Dose of Linezolid (n = 10) | 300 mg/d of Linezolid (n = 20) | |
|---|---|---|---|---|---|
| Any adverse events, No. (%) | 62 (90) | 33 (85) | 29 (97) | 10 (100) | 19 (95) |
| Hematologic, No. (%) | 49 (71) | 25 (64) | 24 (80) | 9 (90) | 15 (75) |
| Leukopenia, No. (%) | 27 (39) | 17 (25) | 10 (33) | 2 (20) | 8 (40) |
| Neutropenia, No. (%) | 7 (10) | 4 (10) | 3 (10) | 1 (10) | 2 (10) |
| Anemia, No. (%) | 34 (49) | 16 (44) | 18 (60) | 7 (70) | 11 (55) |
| Thrombocytopenia, No. (%) | 21 (30) | 10 (26) | 11 (37) | 6 (60) | 5 (25) |
| Neurologic, No. (%) | 45 (65) | 26 (67) | 19 (63) | 7 (70) | 12 (60) |
| Symptoms or diagnosis of peripheral neuropathy, No. (%) | 32 (46) | 18 (46) | 14 (47) | 4 (40) | 10 (50) |
| Optic neuropathy or visual changes, No. (%) | 21 (30) | 10 (26) | 11 (37) | 5 (50) | 6 (30) |
| Other, No. (%) | 2 (2.9) | 1 (2.6) | 1 (3.3) | 0 (0) | 1 (5) |
| Adverse event rate per linezolid-month on 600 mg/d | 0.21 | .20 | 0.32a | 0.44 | 0.28 |
| Adverse event rate per linezolid-month on low dose | N/A | N/A | 0.10a | 0.09 | 0.11 |
Abbreviation: N/A, not available; MDR TB, multidrug-resistant tuberculosis.
a
P = .03.